Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC35 in Adult Participants With Obesity or Overweight
NCT07842640Phase 1Recruiting
- Sponsor
- Ascletis Pharma Inc.
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC35 in obesity (9 cohorts), sponsored by Ascletis Pharma Inc. Primary endpoint: Adverse Events at Day 141. Started Aug 2026; status: recruiting.
02
Drugs
ASC35
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07842640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842640.